MUSTANG BIO: SOARING TO A NEW HIGH AFTER BUBBLE BOY CURE ANNOUNCEMENT
Mustang Bio’s (NASDAQ: MBIO) shares rose by almost 250% after its development partner, St Jude Children’s Research Hospital in Memphis, published study results that demonstrated that its experimental gene therapy could cure “Bubble Boy” disease or X-SCID, a severe combined immunodeficiency in infants. Figure 1 - Stock...
